默沙东300亿美元收购谈判搁浅！

药时代

01/26

出海机会来了！寻找PCSK9小分子抑制剂产品，全球权益，目前所处阶段不限。请感兴趣的公司立即联系：药时代BD团队BD@drugtimes.cn药物开发中杂质鉴定与结构解析的案例研究 | 博腾·药时代直播间正文共：2000字预计阅读时间：6分钟2026年开年，一场超级并购传闻点燃了全球生物医药界。据英国《金融时报》媒体透露，默沙东拟以300亿美元收购Revolution，后者目前市值为227亿美元。...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2606703942"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606703942\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606703942?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-26 19:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2606703942","market":"us","top_or_hot":-1,"title":"默沙东300亿美元收购谈判搁浅！","media":"药时代","content":"<div>\n<p>出海机会来了！寻找PCSK9小分子抑制剂产品，全球权益，目前所处阶段不限。请感兴趣的公司立即联系：药时代BD团队BD@drugtimes.cn药物开发中杂质鉴定与结构解析的案例研究 | 博腾·药时代直播间正文共：2000字预计阅读时间：6分钟2026年开年，一场超级并购传闻点燃了全球生物医药界。据英国《金融时报》媒体透露，默沙东拟以300亿美元收购Revolution，后者目前市值为227亿美元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东300亿美元收购谈判搁浅！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东300亿美元收购谈判搁浅！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-26 19:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b><strong>药时代</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>出海机会来了！寻找PCSK9小分子抑制剂产品，全球权益，目前所处阶段不限。请感兴趣的公司立即联系：药时代BD团队BD@drugtimes.cn药物开发中杂质鉴定与结构解析的案例研究 | 博腾·药时代直播间正文共：2000字预计阅读时间：6分钟2026年开年，一场超级并购传闻点燃了全球生物医药界。据英国《金融时报》媒体透露，默沙东拟以300亿美元收购Revolution，后者目前市值为227亿美元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2461242641.AUD","symbol_name":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b","article_id":"2606703942","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606703942","pubTimestamp":1769426529,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据知情人士透露，默沙东与Revolution的收购谈判已暂时停止，核心分歧在于价格。2026年1月7日，市场传出艾伯维拟超200亿美元收购Revolution，后者股价受此消息影响单日涨超28%。尽管艾伯维迅速下场否认，但随后又传出默沙东加入竞逐，并将估值预期大幅抬升至300亿美元区间。该药2024年贡献了公司近半收入、累计销售超1500亿美元的“现金牛”，一旦专利到期，将留下巨额收入缺口。结语默沙东与Revolution的300亿美元博弈虽暂告段落，但风暴眼并未消散。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","RVMD":"Revolution Medicines, Inc.","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4559":"巴菲特持仓","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","MRK":"默沙东","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU0861579265.USD":"联博低波幅策略股票基金A","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4007":"制药","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","BK4534":"瑞士信贷持仓","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4516":"特朗普概念","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"translate_title":"Merck's $30 billion acquisition negotiations run aground!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1.94,"MRK":1.96},"content_text":"出海机会来了！寻找PCSK9小分子抑制剂产品，全球权益，目前所处阶段不限。请感兴趣的公司立即联系：药时代BD团队BD@drugtimes.cn药物开发中杂质鉴定与结构解析的案例研究 | 博腾·药时代直播间正文共：2000字预计阅读时间：6分钟2026年开年，一场超级并购传闻点燃了全球生物医药界。据英国《金融时报》媒体透露，默沙东拟以300亿美元收购Revolution，后者目前市值为227亿美元。推荐阅读：收购传闻又起！默沙东拟300亿美元收购这家公司…然而不足一个月，这场继辉瑞收购Seagen的超级并购传闻却又传出戏剧性转折。据知情人士透露，默沙东与Revolution的收购谈判已暂时停止，核心分歧在于价格。估值博弈下的暂时休兵回顾此次收购传闻，算得上一波三折。2026年1月7日，市场传出艾伯维拟超200亿美元收购Revolution，后者股价受此消息影响单日涨超28%。尽管艾伯维迅速下场否认，但随后又传出默沙东加入竞逐，并将估值预期大幅抬升至300亿美元区间。截图来源：Revolution消息一出便引发行业震动，KRAS赛道迎来超级狂欢。Erasca等相关企业股价应声大涨，国内劲方医药、加科思等药企也顺势走出连续上涨行情，再次推动了KRAS作为PD-1之后最大癌症靶点的黄金地位。虽然目前的谈判已经搁置，但这并不意味着交易彻底终结，双方仍有可能重启谈判，或者会出现其他竞标者介入。此前，默沙东首席执行官虽强调公司主要关注150亿美元以下的交易，但也对更大规模交易持开放态度，这为未来的变数留下了伏笔。Revolution为何值300亿美元？Revolution的资本溢价，根植于其对RAS蛋白的革命性突破。RAS突变被认为胰腺癌、肺癌、结直肠癌等多个癌种的核心驱动因子，长期被视为“不可成药”。2013年，Kevan Shokat实验室首次报道KRAS G12C突变的“口袋”，打破神话。而Revolution科学顾问委员会正由Shokat领衔，为其技术背书。管线方面，Revolution领先资产Daraxonrasib（RMC-6236）是一种口服的泛RAS抑制剂，能直接作用于处于激活（ON）状态的RAS蛋白，阻断RAS与下游信号蛋白的结合。该药物已进入四项全球III期临床研究，针对胰腺导管腺癌（PDAC）和RAS突变NSCLC。其中，针对胰腺癌的关键研究数据预计于2026年夏季公布，且已获得FDA的优先审评券资格，有望在2026年加速获批。此外，Revolution的另一款KRAS G12D抑制剂RMC-9805，也将于今年启动两项三期临床试验，分别针对一线胰腺癌、一线肺癌；还有一款G12C选择性抑制剂Elironrasib临床数据可观，单药治疗I期研究数据显示，在既往接受过免疫治疗和化疗、但未使用过KRAS G12C抑制剂治疗的NSCLC患者中，每日两次、每次200毫克剂量的治疗组，ORR达到56%。更关键的是，Revolution的RAS抑制剂与默沙东王牌K药（Keytruda）联用潜力已现端倪。Revolution的RMC-6236与Elironrasib两款候选药物，均在临床研究中观察到与PD-1抑制剂联用的潜力。例如，Elironrasib联合K药在PD-L1高表达NSCLC患者中初步ORR达100%，这一点尤为关键。默沙东的“并购焦虑”默沙东愿意为Revolution一掷千金，主要源于迫在眉睫的“专利悬崖”。默沙东最为核心的超级重磅炸弹Keytruda（K药）将于2028年失去关键市场独占权。该药2024年贡献了公司近半收入、累计销售超1500亿美元的“现金牛”，一旦专利到期，将留下巨额收入缺口。尽管默沙东已通过多项交易扩充管线，但市场对其未来增长动能依然深表担忧，这直接导致其股价在2025年于MNC中表现一般。因此，寻找能够填补空白、甚至缔造下一个传奇的资产，已成为默沙东的战略急务。而Revolution，正是其眼中最理想的“解题方案”之一。一方面，Daraxonrasib若成功，可与K药形成“双保险”，延长Keytruda生命周期；另一方面，300亿美元估值仅相当于Keytruda一年收入，但若能锁定未来肿瘤市场，性价比远超竞品。值得一提的是，尽管Revolution估值高，但KRAS赛道的争议远未平息。Revolution采用覆盖KRAS/HRAS/NRAS的泛抑制策略，但动物模型显示，同时抑制三家族RAS可能导致致命毒性。当前市场更关注“仅KRAS抑制”路线的安全性验证，Revolution需证明其泛抑制剂在有效性和毒性间取得平衡。结语默沙东与Revolution的300亿美元博弈虽暂告段落，但风暴眼并未消散。这场谈判不仅是对一家生物技术公司价值的定价，更是对KRAS赛道未来商业潜力的预演，以及对整个制药行业在创新转型和生存压力下战略胆魄的考验。无论交易最终花落谁家，其结果都将在未来5-10年深刻影响全球肿瘤治疗的研发格局与市场竞争态势。Revolution的故事，远未到终章。封面图/摘要图来源：即梦AI国内首个DAC出海合作达成！2026-01-26APSB | 周庆同/王明伟团队揭示Gq和Gi蛋白偶联的GLP-1受体结构特征2026-01-26马斯克宣布2026年进入脑机接口量产时代！三体人点赞2026-01-24破局“十年滞后”：度普利尤单抗如何穿越儿童用药的\"深水区\"？2026-01-23","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}